ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Human Epidermal growth factor Receptor 3 (HER3), encoded by the ERBB3 gene, is a crucial member of the Epidermal Growth Factor Receptor (EGFR) family.
• Despite lacking intrinsic kinase activity, HER3 plays a significant role in cancer development and progression, often through heterodimerization with other receptors like EGFR and HER2.
• Oncogenic mutations in ERBB3 have emerged as critical factors in tumorigenesis.

Purpose of the Study:

• To review the evidence supporting ERBB3 somatic mutations as potential tumoral drivers.
• To highlight the prevalence of ERBB3 mutations across various cancer types.
• To present recent therapeutic strategies targeting oncogenic ERBB3 mutations.

Main Methods:

• Literature review of studies investigating ERBB3 mutations in cancer.
• Analysis of evidence linking ERBB3 mutations to tumor development.
• Summary of clinical studies evaluating therapeutic approaches for ERBB3-mutated cancers.

Main Results:

• ERBB3 mutations are identified as significant drivers in multiple cancer types.
• The frequency of ERBB3 mutations is notable across a range of malignancies.
• Emerging therapies show promise in treating patients with ERBB3-driven cancers.

Conclusions:

• ERBB3 mutations represent actionable targets in oncology.
• Targeting HER3 signaling pathways offers a potential therapeutic avenue for specific cancer patient populations.
• Further research into ERBB3-targeted therapies is warranted to improve cancer treatment efficacy.